DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Information source: Bristol-Myers Squibb
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Candidiasis, Oral; HIV Infections

Intervention: Nystatin (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bristol-Myers Squibb

Summary

To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)

Clinical Details

Official title: Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Allowed:

- Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus

or which stimulate the immune system.

- Systemic or oral antibiotics.

Patients must have AIDS or AIDS-related syndromes (HIV infection:

- Group III or IV, CDC classification) and not have been treated for oral candidiasis

during the past year.

- Patients can be entered into the study who have:

- Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex.

- A positive or negative oral culture for Candida.

- Must be able to follow instructions regarding the use of a pastille.

Exclusion Criteria Co-existing Condition: Patients with the following are excluded:

- Oral lesions diagnostic of oral candidiasis or systemic candidiasis.

- Suspected or proven candidal esophagitis.

Patients with the following are excluded:

- Oral lesions diagnostic of oral candidiasis or systemic candidiasis.

- Receiving any effective antifungal agent orally or intravenously within 72 hours of

study entry.

- Not expected to survive for at least 6 months.

- Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20

minutes twice a day.

- Known hypersensitivity to nystatin.

- Suspected or proven candidal esophagitis.

Prior Medication: Excluded within 72 hours of study entry:

- Any oral or intravenous antifungal agent.

Locations and Contacts

Birmingham Veterans Administration Med Ctr / Univ of Alabama, Birmingham, Alabama 35233, United States

Bristol - Myers Squibb Co, Princeton, New Jersey 085434000, United States

Additional Information

BMS Clinical Trials Disclosure

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm

Related publications:

MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 15;12(5):470-6.


Last updated: October 1, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017